Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DQO46V
|
|||
| Drug Name |
CT-388
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66] | Phase 1 | [1] | |
| Type 2 diabetes [ICD-11: 5A11; ICD-10: E08-E13] | Phase 1 | [1] | ||
| Company |
Carmot Therapeutics Berkeley, CA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Gastric inhibitory polypeptide receptor (GIPR) | Target Info | Modulator | [2] |
| Glucagon-like peptide 1 receptor (GLP1R) | Target Info | Modulator | [2] | |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Insulin secretion | ||||
| Reactome | Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | |||
| G alpha (s) signalling events | ||||
| Glucagon-type ligand receptors | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04838405) A Phase 1 Randomized, Double Blind, Placebo Controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CT-388 in Otherwise Healthy Overweight and Obese Adult Participants and in Obese Patients With Type 2 Diabetes Mellitus. U.S.National Institutes of Health. | |||
| REF 2 | Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opin Emerg Drugs. 2021 Sep;26(3):231-243. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.